Salubris(SZ:002294) Xin Lang Cai Jing·2025-10-09 02:33Core Viewpoint - The stock of Shenzhen Xinlitai Pharmaceutical Co., Ltd. has experienced significant fluctuations, with a year-to-date increase of 94.35% and recent declines in the short term [1][2]. Company Overview - Shenzhen Xinlitai Pharmaceutical Co., Ltd. was established on November 3, 1998, and listed on September 10, 2009. The company is located in the Futian District of Shenzhen, Guangdong Province [1]. - The main business segments include pharmaceuticals and medical devices, with revenue composition as follows: formulations 81.69%, devices 8.54%, raw materials 7.17%, and others 2.59% [1]. Financial Performance - For the first half of 2025, Xinlitai achieved operating revenue of 2.131 billion yuan, representing a year-on-year growth of 4.32%. The net profit attributable to shareholders was 365 million yuan, with a growth of 6.10% [2]. - Since its A-share listing, the company has distributed a total of 7.204 billion yuan in dividends, with 1.649 billion yuan distributed over the past three years [3]. Shareholder Structure - As of June 30, 2025, the number of shareholders was 24,000, a decrease of 0.79% from the previous period. The average circulating shares per person increased by 0.80% to 46,403 shares [2]. - The top circulating shareholders include China Europe Medical Health Mixed A (holding 26.163 million shares), Hong Kong Central Clearing Limited (holding 15.307 million shares), and ICBC Frontier Medical Stock A (holding 15 million shares) [3].